AI model diagnoses COVID-19 in routine blood tests with impressive accuracy

AI models can be trained to diagnose COVID-19 using routine laboratory blood tests, according to new research published in Biomedical Signal Processing and Control.

“With new mutations of the virus with higher transmission rates, it is imperative to diagnose positive cases as quickly and accurately as possible,” wrote first author Samin Babaei Rikan, a specialist with the department of computer engineering at Urmia University in Iran, and colleagues. “Therefore, a fast, accurate, and automatic system for COVID-19 diagnosis can be very useful for clinicians.”

The group noted that PCR tests, chest X-rays and chest CT scans are all currently used to diagnose COVID-19—but all three have their own faults that make them less than ideal. To see if they could potentially provide clinicians with another option, Rikan et al. tested the ability of seven machine learning models and four deep learning models to diagnose COVID-19 using routing blood tests. Each model was developed and trained using three different datasets of blood tests that contained positive and negative COVID-19 cases.

Overall, the group had the most consistent success with the deep neural network (DNN) model. For the three datasets, its accuracy was measured as 92.11%, 93.16% and 93.33%, respectively. The model’s sensitivity (96.14%, 93.27% and 77.05%) and specificity (84.56%, 93.02% and 95.27%) for the three different datasets results were also especially strong.

The model’s area under the ROC curve for the three datasets, meanwhile, were 92.2%, 93.2% and 85.97%. The DNN was also faster and more efficient than any other AI model, the authors added.

“Based on the obtained results, it can be said that the DNN model proposed in this study is among the most accurate and fastest models introduced in the literature to date,” the authors wrote. “Our proposed model is an automated tool that can help clinicians to diagnose the COVID-19 disease. Using AI-based models for COVID-19 diagnosis is more accurate than traditional methods that require experience and time to diagnose.”

Read the full analysis here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.